Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cancer Genetics Launches New Genetic Test for Cervical Cancer Management

Published: Wednesday, July 24, 2013
Last Updated: Wednesday, July 24, 2013
Bookmark and Share
A published research study highlights the relevance of FHACT™ in screening women with high risk of cervical cancer.

Cancer Genetics, Inc. launched its proprietary cervical cancer test and is marketing the molecular product globally through its network of distribution partners. Cervical cancer is the second most common cancer in women worldwide, with 500,000 new cases annually and almost 80% of cases occurring in developing countries.

CGI’s FISH-based HPV-Associated Cancer Test (FHACT™) uses a unique combination of genetic markers to detect genetic abnormalities located at 3q, 5p, 20q and chromosome 7. A recent study concluded that these four biomarkers are associated with the severity of cervical lesions. The findings of the study, published in the July issue of Gynecologic Oncology, http://dx.doi.org/10.1016/j.ygyno.2013.06.005, support the use of FHACT™ as an aid in the screening of women with HPV-positive abnormal cervical lesions. By identifying lesions that will progress to a higher grade versus those that will regress, FHACT™ can allow for a better triage of patients before referral for colposcopy and consequently reduce the associated healthcare burden.

The test can be performed directly on Pap smear or liquid based-cytology and does not require any resampling. It is therefore an ideal fit in countries where women have reduced access to routine screening. “We think that FHACT™ will be a new tool to help identify women with high risk of progressing to cervical cancer,” says Dr. Q. Annie Hasan, Ph.D., F.N.A.Sc., Head of Department and Senior Consultant, Department of Genetics and Molecular Medicine, Kamineni Hospitals, Hyderabad, India. “This is particularly important in India due to the rising incidence of cervical cancer caused by difficulty in implementation of cervical screening programs, which require repeated evaluation in large number of women.” In partnership with its distributors and collaborators, CGI will conduct workshops in India and Mexico to accelerate adoption of FHACT™ amongst the clinical community.

In industrialized countries, it is estimated that about one million women undergo colposcopy procedures each year, while only 3,700 cancer cases are actually diagnosed. The Company expects FHACT™ to aid in lowering healthcare costs and reducing the number of unwarranted colposcopies by providing genomic information of the lesion not available until now. CGI plans to make FHACT™ available in the U.S. later this year and will be working closely with several laboratories and hospitals to implement an early adoption of the test.

The design and development of FHACT™ was supported in part by a Small Business Innovation Research (SBIR) grant. In addition to cervical cancer, FHACT™ is applicable to other HPV-associated cancers. CGI is currently conducting ongoing validations with key thought leaders for head and neck cancer and anal cancer. Results from these studies are expected to be available by year end.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cancer Genetics, Roche Expand Agreement
Companies expand molecular diagnostic cancer testing in Central America and the Caribbean.
Tuesday, February 11, 2014
Cancer Genetics, Inc. Announces Pricing of Initial Public Offering of 600,000 Shares of Common Stock
Cancer Genetics, Inc. announced the pricing of its initial public offering of 600,000 shares of its common stock at a price to the public of $10.00 per share.
Monday, April 08, 2013
CGI and Aptiv Solutions Form Strategic Partnership Focused on Creating More Effective Clinical Trials in Oncology
Partnership to help biotechnology and pharmaceutical companies bring next generation oncology therapeutics to market in a more targeted and effective manner.
Saturday, March 26, 2011
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Discovered Through ‘Big Data’ Analysis
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Virus Inspired Cell Cargo Ships
Virus-inspired container design may lead to cell cargo ships following construction of ten large, two-component, icosahedral protein complexes.
Uncovering a New Principle in Chemotherapy Resistance in Breast Cancer
The NIH study has revealed an entirely unexpected process for acquiring drug resistance that bypasses the need to re-establish DNA damage repair in breast cancers that have mutant BRCA1 or BRCA2 genes.
Understanding Treatment Resistant Melanoma
Researchers have determined how advanced melanoma becomes resistant; a development toward developing treatments.
Liquid Biopsies: DNA Size Matters
Study finds circulating tumour DNA can be distinguished from healthy DNA through fragment size identification.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!